<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Medicines &#8211; Polypharma: Generics Developer</title>
	<atom:link href="https://polypharma.de/en/category/medicines/feed/" rel="self" type="application/rss+xml" />
	<link>https://polypharma.de</link>
	<description>Full-service in the production of generics and delivery of raw materials in Africa and the Middle East</description>
	<lastBuildDate>Tue, 14 Sep 2021 09:20:13 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://polypharma.de/wp-content/uploads/2020/07/cropped-Polypharma-Technologies-and-Sciences-Hamburg-150x150.png</url>
	<title>Medicines &#8211; Polypharma: Generics Developer</title>
	<link>https://polypharma.de</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Polypharma celebrates 30th Anniversary</title>
		<link>https://polypharma.de/en/2021/06/polypharma-celebrates-30th-anniversary/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Fri, 18 Jun 2021 08:27:42 +0000</pubDate>
				<category><![CDATA[Counterfeit Medicines]]></category>
		<category><![CDATA[Development / Dossiers]]></category>
		<category><![CDATA[Factory construction]]></category>
		<category><![CDATA[Fairs / Events]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Innovation]]></category>
		<category><![CDATA[Manufacturing Process]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Pharmaceutical Raw Materials / Laboratory Equipment]]></category>
		<category><![CDATA[Registration Process]]></category>
		<category><![CDATA[30 years]]></category>
		<category><![CDATA[30th anniversary]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[construction]]></category>
		<category><![CDATA[Consultant]]></category>
		<category><![CDATA[Developer]]></category>
		<category><![CDATA[Dossier development]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[Drug Master File]]></category>
		<category><![CDATA[food supplements]]></category>
		<category><![CDATA[generic manufacture]]></category>
		<category><![CDATA[MENA]]></category>
		<category><![CDATA[Middle East]]></category>
		<category><![CDATA[Polypharma]]></category>
		<category><![CDATA[Polypharma tech]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[raw material]]></category>
		<category><![CDATA[Sciences]]></category>
		<category><![CDATA[sourcing]]></category>
		<category><![CDATA[supply]]></category>
		<category><![CDATA[Technologies]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=8650</guid>

					<description><![CDATA[Single partner Polypharma offers a unique blend of services and skills that make it possible for it to act as a single partner accompanying local companies all the way from selection of target product through to actual receipt of raw materials for production. “Over the years we have developed more than 200 approved drug dossiers [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Sodium Alendronate as drinking solution and effervescent tablet</title>
		<link>https://polypharma.de/en/2020/07/sodium-alendronate-as-drinking-solution-and-effervescent-tablet/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Mon, 27 Jul 2020 11:40:54 +0000</pubDate>
				<category><![CDATA[Medicines]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6617</guid>

					<description><![CDATA[Sodium alendronate, which belongs to the group of biphosphonates, has been released as a new drinking solution on the French market. The drinkable solution is easy to take and is quickly absorbed. The active substance is indicated for postmenopausal osteoporosis and reduces the risk of vertebral and hip fractures.]]></description>
		
		
		
			</item>
		<item>
		<title>EU approval of the first triple combination for asthma</title>
		<link>https://polypharma.de/en/2020/07/eu-approval-of-the-first-triple-combination-for-asthma/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Wed, 22 Jul 2020 11:39:41 +0000</pubDate>
				<category><![CDATA[Medicines]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6615</guid>

					<description><![CDATA[The drug belonging to the DPI group administered in hard capsules consists of the ingredients indacaterol/glycopyrronium/mometasone (114 µg / 46 µg / 68 µg). This fixed tri-therapy is used in patients with insufficiently controlled asthma with a combination of a long-acting beta-2 agonist (LABA) and a high dose of an inhaled corticosteroid (ICS) as maintenance [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>New oral formulation with Diclofenac</title>
		<link>https://polypharma.de/en/2020/07/new-oral-formulation-with-diclofenac/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Tue, 21 Jul 2020 11:38:40 +0000</pubDate>
				<category><![CDATA[Innovation]]></category>
		<category><![CDATA[Medicines]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6613</guid>

					<description><![CDATA[In France, 50 mg of diclofenac epolamine granules for oral suspension in sachets have been granted marketing authorisation and are now available. The field of application extends over: short-term symptomatic treatment of acute seizures of extraarticular rheumatism such as scapulo-humerus periarthritis, tendonitis and mucosal inflammation in adolescents (over 15 years of age) and adults; microcrystalline [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Why a market analysis of your own market is so important</title>
		<link>https://polypharma.de/en/2020/07/why-a-market-analysis-of-your-own-market-is-so-important/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Thu, 09 Jul 2020 11:35:15 +0000</pubDate>
				<category><![CDATA[Medicines]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6604</guid>

					<description><![CDATA[A market analysis is usually considered superfluous, here are a few reasons to change your mind: Markets and customers, and/or the top 10 diseases are changing: A market analysis helps to uncover the sometimes slow, sometimes fast changes in the market and not to lose sight of them. The market analysis method must be properly [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Higher dosage of dulaglutide safe and effective in type 2 diabetes</title>
		<link>https://polypharma.de/en/2020/05/higher-dosage-of-dulaglutide-safe-and-effective-in-type-2-diabetes/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Fri, 29 May 2020 11:29:17 +0000</pubDate>
				<category><![CDATA[Medicines]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6594</guid>

					<description><![CDATA[The AWARD-11 study demonstrates that people with type 2 diabetes receiving a higher weekly dose of 3mg and/or 4.5mg instead of 0.75mg and 1.5mg administered by subcutaneous injections would see an improvement in blood glucose levels and weight loss. https://www.gelbe-liste.de/diabetologie/dulaglutid-typ2-diabetes]]></description>
		
		
		
			</item>
		<item>
		<title>Medicines produced by 3D printer</title>
		<link>https://polypharma.de/en/2020/05/medicines-produced-by-3d-printer/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Tue, 26 May 2020 11:25:04 +0000</pubDate>
				<category><![CDATA[Medicines]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6588</guid>

					<description><![CDATA[Research using 3D printers is entering its next phase. Research is being carried out into how tablets can be produced in the future using 3D printing. Here the starting substances for the medicines are mixed and melted in a pharmaceutical melt extruder and processed into filaments. The filaments can then be melted a second time [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Reduction of concomitant diseases in stable coronary heart disease and diabetes mellitus</title>
		<link>https://polypharma.de/en/2020/05/reduction-of-concomitant-diseases-in-stable-coronary-heart-disease-and-diabetes-mellitus/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Tue, 19 May 2020 11:20:06 +0000</pubDate>
				<category><![CDATA[Medicines]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6582</guid>

					<description><![CDATA[In a COMPASS study (Cardiovascular Outcomes for People Using Anticoagulation Strategies), taking 100mg of aspirin and 2.5mg of rivaroxaban twice daily demonstrated that the risk of myocardial infarction or stroke was significantly reduced. Cardiovascular mortality and all-cause mortality were also reduced. In patients with diabetes who have a higher risk of mortality, their absolute risk [&#8230;]]]></description>
		
		
		
			</item>
		<item>
		<title>Dapagliflozin tablets for type 2 diabetes</title>
		<link>https://polypharma.de/en/2020/05/dapagliflozin-tablets-for-type-2-diabetes/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Fri, 15 May 2020 11:19:26 +0000</pubDate>
				<category><![CDATA[Medicines]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6580</guid>

					<description><![CDATA[Dapagliflozin is the first molecule in the class of SGLT2 inhibitors to be marketed in France alone or in combination with metformin. Studies show that this oral antidiabetic reduces the morbidity and mortality of type 2 diabetics and helps prevent hospitalisation for heart failure. https://www.lemoniteurdespharmacies.fr/revues/le-moniteur-des-pharmacies/article/n-3320/forxiga-inaugure-une-nouvelle-classe-dans-le-diabete-de-type-2.html?utm_source=24h-mpl&#38;utm_medium=newsletter&#38;utm_content=actu]]></description>
		
		
		
			</item>
		<item>
		<title>Solriamfetol film-coated tablets for narcolepsy and sleep apnea</title>
		<link>https://polypharma.de/en/2020/05/solriamfetol-film-coated-tablets-for-narcolepsy-and-sleep-apnea/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Wed, 13 May 2020 11:17:12 +0000</pubDate>
				<category><![CDATA[Medicines]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6576</guid>

					<description><![CDATA[A new drug for the treatment of narcolepsy and obstructive sleep apnea is coming to market in Germany in the form of Solriamfetol 75mg and 150mg film-coated tablets. Solriamfetol is a psychoanaleptic that inhibits the reuptake of dopamine and noradrenaline. http://news.gelbe-liste.de/c/33246521/7c295f2a515a1-1fc7bog]]></description>
		
		
		
			</item>
		<item>
		<title>Dapagliflozin 5mg and 10mg film-coated tablet helps with heart failure</title>
		<link>https://polypharma.de/en/2020/05/dapagliflozin-5mg-and-10mg-film-coated-tablet-helps-with-heart-failure/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Mon, 04 May 2020 11:13:44 +0000</pubDate>
				<category><![CDATA[Medicines]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6570</guid>

					<description><![CDATA[The SGLT-2 inhibitor (sodium-glucose cotransporter 2) dapagliflozin counteracts progression of heart failure and death of cardiovascular cause in heart failure patients with impaired left ventricular function, regardless of diabetes status. SGLT-2 inhibitors are currently approved for the treatment of type-II diabetes mellitus. https://www.gelbe-liste.de/kardiologie/dapagliflozin-herzinsuffizienz]]></description>
		
		
		
			</item>
		<item>
		<title>New paracetamol- and caffeine-based analgesic</title>
		<link>https://polypharma.de/en/2020/05/new-paracetamol-and-caffeine-based-analgesic/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Mon, 04 May 2020 11:12:50 +0000</pubDate>
				<category><![CDATA[Medicines]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6568</guid>

					<description><![CDATA[Paracetamol (500mg) and caffeine (50mg) tablets are used for the symptomatic treatment of pain of mild to moderate intensity and/or febrile conditions. These may be permitted for adults and children weighing 50kg or more (15 years and older) and may be issued without a doctor&#8217;s prescription. https://www.vidal.fr/actualites/imprimer/24833/prontadol_adultes_nouveau_medicament_antalgique_a_base_de_paracetamol_et_de_%E2%80%A6]]></description>
		
		
		
			</item>
		<item>
		<title>Clinical trial of a COVID-19 vaccine approved in Germany</title>
		<link>https://polypharma.de/en/2020/04/clinical-trial-of-a-covid-19-vaccine-approved-in-germany/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Wed, 22 Apr 2020 11:10:33 +0000</pubDate>
				<category><![CDATA[Medicines]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6564</guid>

					<description><![CDATA[In a press release today, the Paul Ehrlich Institute (PEI) announced that it has approved the first clinical trial of a vaccine against COVID-19 in Germany. It is a ribonucleic acid (RNA) vaccine. https://www.gelbe-liste.de/nachrichten/corona-impfstoff-klinische-studie]]></description>
		
		
		
			</item>
		<item>
		<title>Givosarin 189mg/ml solution for injection</title>
		<link>https://polypharma.de/en/2020/04/givosarin-189mg-ml-solution-for-injection/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Wed, 15 Apr 2020 11:00:38 +0000</pubDate>
				<category><![CDATA[Medicines]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6562</guid>

					<description><![CDATA[Givosiran 189mg/ml solution for injection is the first drug approved in Europe for the treatment of acute hepatic porphyria (AHP). It is an RNAi drug with which a gene can be silenced. Until now, there has been no approved drug therapy for patients with AHP. https://www.gelbe-liste.de/neue-medikamente/givlaari-givorisan-hepatische-porphyrie]]></description>
		
		
		
			</item>
		<item>
		<title>Rimegepant 75mg orodispersible tablet for migraine treatment</title>
		<link>https://polypharma.de/en/2020/03/rimegepant-75mg-orodispersible-tablet-for-migraine-treatment/</link>
		
		<dc:creator><![CDATA[Liza Knezlova]]></dc:creator>
		<pubDate>Mon, 16 Mar 2020 10:51:29 +0000</pubDate>
				<category><![CDATA[Medicines]]></category>
		<guid isPermaLink="false">https://polypharma.de/?p=6548</guid>

					<description><![CDATA[The US FDA has approved the Rimegepant 75mg orodispersible tablet. The freeze-dried tablet should dissolve almost immediately in the mouth without water and provide a convenient, discreet way to take migraine medication. https://www.cphi-online.com/catalent-partners-with-biohaven-on-newlyapproved-news082625.html?utm_campaign=HLN00CPO-GC-NewsletterWeek12&#38;utm_emailname=HLN00CPO-GC-NewsletterWeek12&#38;utm_medium=email&#38;utm_source=Eloqua&#38;utm_MDMContactID=7124c9da-0506-4007-b30e-81ecc9c9c575&#38;utm_campaigntype=Newsletter&#38;utm_sub=Latest%20Pharma%20Supply%20Chain%20News&#38;eM=72aa981ef401a1f83acaf77df3cd34f7e9bb75061f2959aa7de7caa55413825f&#38;eventSeriesCode=ES_CPHLONL&#38;eventEditionCode=HLN00CPO&#38;SessionCode=S_CPHLONNWSLTR]]></description>
		
		
		
			</item>
	</channel>
</rss>
